
ZBH Stock Forecast & Price Target
ZBH Analyst Ratings
Bulls say
Zimmer Biomet Holdings has demonstrated a robust financial performance, with key segments such as knees and hips experiencing growth rates of 5.3% and 3.8% respectively on a constant currency basis, signaling solid demand in the orthopedic market. The company has successfully executed a turnaround strategy that is supported by recent product innovations and strategic mergers and acquisitions, contributing to an overall upward trend in top-line growth. Additionally, Zimmer Biomet's healthy balance sheet and alignment with fiscal year 2025 revenue growth targets further underscore a promising outlook for the firm in the competitive orthopedic space.
Bears say
Zimmer Biomet Holdings (ZBH) is facing challenges with flat average selling prices (ASP) projected for FY25, coupled with a modest headwind from selling day differences impacting growth. The company’s recent performance reveals lower growth rates for its Knee segment relative to peers, with the Hip segment showing the weakest performance, leading to a downward revision of operating margins for Q3 and Q4. Additionally, ZBH’s updated guidance highlights persistent weaknesses in restorative therapies and slower organic growth, particularly in overseas markets, contributing to a negative outlook given the firm's execution difficulties and competitive pressures.
This aggregate rating is based on analysts' research of Zimmer Biomet Hlds and is not a guaranteed prediction by Public.com or investment advice.
ZBH Analyst Forecast & Price Prediction
Start investing in ZBH
Order type
Buy in
Order amount
Est. shares
0 shares